Nintedanib is an orally administered small molecule tyrosine kinase inhibitor with antifibrotic activity, targeting PDGFR, FGFR, and VEGFR signaling, and investigated in COVID-19 for the prevention and treatment of SARS-CoV-2-induced pulmonary fibrosis.
Jul 31 2021 |
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.05.055 | Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study |
| 14% lower mortality (p=1) and 34% improvement (p=0.03). Analysis of 60 mechanically ventilated COVID-19 patients (30 nintedanib, 30 historical controls) showing no significant difference in 28-day mortality or the need for mechanical ventilation, but shorter mechanical ventilation duration (p=.. | ||